US Drug Recall Register
Class II · Moderate risk Terminated Initiated Feb 9, 2018 (9 years ago)

Tretinoin USP for prescription compounding

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

What was recalled

Tretinoin USP for prescription compounding, packaged in a) 5g (NDC 58597-8033-2); 1b) 10g (NDC 58597-8033-3); c) 25g (NDC 58597-8033-4), RX only, packed by American Pharmaceutical Ingredients, LLC 6650 Highland Road, Waterford, MI 48327

Recalling firm
American Pharmaceutical Ingredients LLC
NDC code
58597-8033-2
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0530-2018

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Tretinoin recalls

See all
Class II · Moderate risk Ongoing

Claravis

Reason Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin

Teva Pharmaceuticals USA, Inc NDC 0555-1054-56 D-0521-2026
Class II · Moderate risk Ongoing

Amnesteem

Reason Failed Dissolution Specifications

Mylan Pharmaceuticals INC NDC 0378-6614-93 D-0399-2026
Class II · Moderate risk Ongoing

Isotretinoin Capsules

Reason Superpotent and Subpotent

Teva Pharmaceuticals USA, Inc NDC 0591-2436-15 D-0446-2026
Class II · Moderate risk Ongoing

Isotretinoin Capsules

Reason Superpotent and Subpotent

Teva Pharmaceuticals USA, Inc NDC 0591-2435-15 D-0445-2026
Class II · Moderate risk Ongoing

Isotretinoin Capsules

Reason Superpotent Drug: The 3-month stability result for assay was found to be above specification limit

Teva Pharmaceuticals USA, Inc NDC 0591-2436-45 D-0439-2024